Fig 1: Effect of S63845 treatment on megakaryocytic differentiation in CB6F1 mice. (A) Representative FACS profiles and percentages of MEP, CD45+CD41+, CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in BM cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (B) Representative FACS profiles and percentages of MEP, CD45+CD41+, CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in SP cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (C) Representative FACS profiles and percentages of MEP, CD45+CD41+, CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in BM cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (D) Representative FACS profiles and percentages of MEP, CD45+CD41+, CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in SP cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (E) Representative FACS profiles and percentages of CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in PB cells of control and S63845-treated mice on day 7. Control, n = 5; 25 mg/kg, n = 5; 50 mg/kg, n = 4. (F) Representative FACS profiles and percentages of CD45−CD41+, CD45−CD41+CD42d+, and CD45−CD42d+ subpopulations in PB cells of control and S63845-treated mice on day 22. Control, n = 6; 25 mg/kg, n = 5; 50 mg/kg, n = 4. All data represent the means ± SEM compared with control unless otherwise specified. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns = not significant according to two-tailed unpaired Students’ t-test. MEP: megakaryocyte-erythroid progenitor.